IL239213B - Preparations and methods for capturing cellular targets of biologically active substances - Google Patents

Preparations and methods for capturing cellular targets of biologically active substances

Info

Publication number
IL239213B
IL239213B IL239213A IL23921315A IL239213B IL 239213 B IL239213 B IL 239213B IL 239213 A IL239213 A IL 239213A IL 23921315 A IL23921315 A IL 23921315A IL 239213 B IL239213 B IL 239213B
Authority
IL
Israel
Prior art keywords
bioactiv
capture
agents
compositions
methods
Prior art date
Application number
IL239213A
Other languages
English (en)
Hebrew (he)
Other versions
IL239213A0 (en
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of IL239213A0 publication Critical patent/IL239213A0/en
Publication of IL239213B publication Critical patent/IL239213B/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • G01N33/54333Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
IL239213A 2012-12-12 2015-06-04 Preparations and methods for capturing cellular targets of biologically active substances IL239213B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736426P 2012-12-12 2012-12-12
US201361788313P 2013-03-15 2013-03-15
PCT/US2013/074756 WO2014093671A1 (en) 2012-12-12 2013-12-12 Compositions and methods for capture of cellular targets of bioactive agents

Publications (2)

Publication Number Publication Date
IL239213A0 IL239213A0 (en) 2015-07-30
IL239213B true IL239213B (en) 2020-03-31

Family

ID=50934961

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239213A IL239213B (en) 2012-12-12 2015-06-04 Preparations and methods for capturing cellular targets of biologically active substances

Country Status (11)

Country Link
US (2) US9551705B2 (enExample)
EP (1) EP2931305B1 (enExample)
JP (2) JP6484178B2 (enExample)
KR (2) KR102272233B1 (enExample)
CN (1) CN104853767B (enExample)
AU (2) AU2013359160B2 (enExample)
BR (1) BR112015013715A2 (enExample)
CA (1) CA2894432C (enExample)
IL (1) IL239213B (enExample)
SG (1) SG11201504520XA (enExample)
WO (1) WO2014093671A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4159833A3 (en) 2009-12-09 2023-07-26 The Procter & Gamble Company Fabric and home care products
EP2782916B1 (en) * 2011-11-21 2018-02-28 Promega Corporation Carboxy x rhodamine analogs
BR112015013715A2 (pt) 2012-12-12 2017-09-26 Promega Corp sistema, método para capturar o alvo celular, lisado celular e ligante de captura.
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
US11072811B2 (en) 2013-03-15 2021-07-27 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
JP6876002B2 (ja) * 2015-06-05 2021-05-26 プロメガ コーポレイションPromega Corporation 機能的要素を共有結合により係留させるための細胞透過性、細胞適合性、かつ開裂可能であるリンカー
US10458988B2 (en) * 2017-03-03 2019-10-29 Musc Foundation For Research Development Biotinylated luminescent probe
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12180581B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US12181452B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
WO2020191339A1 (en) 2019-03-20 2020-09-24 Promega Corporation Photoaffinity probes
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
US12352734B2 (en) 2020-09-24 2025-07-08 Waters Technologies Corporation Chromatographic hardware improvements for separation of reactive molecules
JP2022182394A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
EP4370109A4 (en) * 2021-07-14 2025-10-22 Univ Maryland SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES AND NANOPARTICLES, AND METHODS OF USE THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
EP0575955B1 (en) 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
WO1994009056A1 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Chelating polymers
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
US20020004202A1 (en) 2000-01-24 2002-01-10 Cornish Virginia W. In vivo screen using chemical inducers of dimerization
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
EP2455457B1 (en) 2003-01-31 2015-03-11 Promega Corporation Covalent tethering of functional groups to proteins
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
EP1989548A2 (en) * 2006-02-08 2008-11-12 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules
JP5420198B2 (ja) * 2008-06-16 2014-02-19 オリンパス株式会社 タンパク質相互作用解析方法、ポリヌクレオチド、および、組成物
KR100891456B1 (ko) 2008-11-06 2009-04-01 씨지케이 주식회사 생리활성물질에 대한 세포내 표적물질을 검출하는 방법 및 장치
WO2010127368A1 (en) 2009-05-01 2010-11-04 Promega Corporation Synthetic oplophorus luciferases with enhanced light output
SG10202103336SA (en) * 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
BR112015013715A2 (pt) 2012-12-12 2017-09-26 Promega Corp sistema, método para capturar o alvo celular, lisado celular e ligante de captura.
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
US11072811B2 (en) * 2013-03-15 2021-07-27 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
JP6876002B2 (ja) * 2015-06-05 2021-05-26 プロメガ コーポレイションPromega Corporation 機能的要素を共有結合により係留させるための細胞透過性、細胞適合性、かつ開裂可能であるリンカー

Also Published As

Publication number Publication date
US10976312B2 (en) 2021-04-13
KR20200103867A (ko) 2020-09-02
KR20150093222A (ko) 2015-08-17
CA2894432A1 (en) 2014-06-19
IL239213A0 (en) 2015-07-30
EP2931305A4 (en) 2016-08-17
AU2019201035B2 (en) 2020-09-03
AU2019201035A1 (en) 2019-03-07
KR102272233B1 (ko) 2021-07-01
US9551705B2 (en) 2017-01-24
JP2019092517A (ja) 2019-06-20
JP6999589B2 (ja) 2022-02-04
AU2019201035B9 (en) 2021-02-11
AU2013359160B2 (en) 2018-11-15
EP2931305A1 (en) 2015-10-21
AU2013359160A1 (en) 2015-07-09
CN104853767B (zh) 2017-04-05
EP2931305B1 (en) 2018-11-28
BR112015013715A2 (pt) 2017-09-26
JP2016502843A (ja) 2016-02-01
CA2894432C (en) 2022-06-07
SG11201504520XA (en) 2015-07-30
CN104853767A (zh) 2015-08-19
KR102227321B1 (ko) 2021-03-12
US20170115283A1 (en) 2017-04-27
US20140199712A1 (en) 2014-07-17
JP6484178B2 (ja) 2019-03-13
WO2014093671A1 (en) 2014-06-19
AU2013359160A2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
IL239213B (en) Preparations and methods for capturing cellular targets of biologically active substances
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
IL237315A0 (en) Method and preparations for cellular immunotherapy
ZA201502880B (en) Compositions and methods for immunotherapy
IL231768B (en) Preparations and methods for testing toxicity
IL238943B (en) Controlled release preparations and methods of using them
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
IL227593A0 (en) Methods and compounds for the preparation of noribogaine from wakengin
GB201411762D0 (en) Precoating methods and compositions
GB201315350D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
GB201315347D0 (en) Methods and compositions
GB201116340D0 (en) Compositions and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed